TargetMol

4-Diethylamino-2-butyn-1-ol

Product Code:
 
TAR-T0555
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0555-5mg5mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0555-10mg10mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0555-25mg25mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0555-50mg50mg£158.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0555-100mg100mg£185.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0555-200mg200mg£232.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
4-Diethylamino-2-butyn-1-ol is used as pharmaceutical intermediates.
CAS:
10575-25-4
Formula:
C8H15NO
Molecular Weight:
141.214
Purity:
0.98
SMILES:
CCN(CC)CC#CCO

References

1. Zorbist, R., Schmid, B., Feick, A., Quan, D., & Sanders, S. (2001). Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers.?Send To Pharm Res.,?18(1), 1029-34. 2. Chancellor, M. (2001). A comparison of the effects of saliva output of oxybutynin chloride and tolterodine tartrate.?Clinical Therapeutics,?23(5), 753-760. doi: 10.12016/s20149-2918(01)820024-2 3. Hughes, K., Lang, J., Lazare, R., Gordon, D., Stanton, S., Malone-Lee, J., & Geraint, M. (1992). Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers.?Xenobiotica,?22(7), 859-869. doi: 10.3109/200498259209053145